Radiation Oncology Journal

  • 제25권1호
  • /
  • Pages.34-42
  • /
  • 2007
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지

국소진행성 직장암의 수술 전 동시화학방사선요법의 결과

Results of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer

  • 최상규 (한림대학교 의과대학 방사선종양학교실) ;
  • 김수산 (한림대학교 의과대학 방사선종양학교실) ;
  • 배훈식 (한림대학교 의과대학 방사선종양학교실)
  • Choi, Sang-Gyu (Department of Radiation Oncology, Hallym University Sacred Heart Hospital) ;
  • Kim, Su-Ssan (Department of Radiation Oncology, Hallym University Sacred Heart Hospital) ;
  • Bae, Hoon-Sik (Department of Radiation Oncology, Hallym University Sacred Heart Hospital)
  • 발행 : 2007.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적: 국소적으로 진행된 직장암환자에서 수술 전 동시화학방사선요법을 시행한 환자들의 항문 괄약근 보존율과 병기 강하율 등을 분석하고자 후향적 임상 연구를 시행하였다. 대상 및 방법: 2002년 1월부터 2005년 12월까지 조직학적으로 확진된 직장암 환자 중, 병기가 T2 이상이거나 림프절 전이가 있는 환자를 대상으로 하였다. 한림대학교 성심병원 방사선종양학과에서 수술 전 동시화학방사선요법을 시행 받은 36명 중, 본원에서 수술을 시행한 26명을 대상으로 연구를 시행하였다. 환자들은 수술 전 병기결정을 위한 검사를 시행하였고 방사선치료는 CT를 촬영하여 치료계획을 세웠으며 매일 1.8 Gy로 주 5회, 총 방사선 조사량 $45.0{\sim}52.2\;Gy$까지 3차원 방사선치료 방법으로 시행하였으며, 방사선치료 첫째 주와 다섯째 주에 5-FU와 leucovorine을 동시 투여하였다. 수술은 동시화학방사선요법 종료 후 약 $2{\sim}4$주경에 시행하였다. 결 과: 대상 환자의 연령 중앙값은 61.9세($34{\sim}78$)였으며, 남자가 21명, 여자가 5명이었고 추적 관찰 기간의 중앙값은 28개월($11{\sim}44$)이었다. 모든 환자에서 절제연 음성인 근치절제가 가능하였으나 병리적으로 완전 반응을 보인 경우는 없었다. 수술은 3예에서 복회음부 절제술을, 나머지 23예에서 하전방절제술이 시행되어 괄약근 보존율은 88.5% (23/26)였다. 수술 후 병기 강하는 12예로 병기 강하율은 46.2%였으며 19예에서 종양 크기가 감소되어 종양크기 감소율은 73%였다. 국소 재발이 1명, 원격 전이가 3명에서 관찰되었으며 3년 무재발 생존율은 96.7%, 3년 무전이 생존율은 87%, 그리고 3년 무진행 생존율은 83.1%였다. 치료와 관련된 급성 독성으로는 Grade 3 & 4 빈혈 각각 1예, Grade 3 백혈구 감소증 1예, Grade 3 장폐색 1예가 관찰되었다. 결 론: 직장암 환자들에서 수술 전 동시화학방사선요법은 근치적 수술을 시행한 경우 높은 괄약근보존율과 수술 후 병기감소율을 보였으며 치료에 따른 독성도 대부분 경미하고 높은 순응도를 보여 효과적인 방법으로 판단되며 앞으로 많은 환자들을 대상으로 장기간에 걸친 추적 관찰을 요한다.

[ $\underline{Purpose}$ ]: We performed a retrospective non-randomized clinical study of locally advanced rectal cancer, to evaluate the anal sphincter preservation rates, down staging rates and survival rates of preoperative chemoradiotherapy. $\underline{Materials\;and\;Methods}$: From January 2002 to December 2005, patients with pathologically confirmed rectal cancer with clinical stage T2 or higher, or patients with lymph node metastasis were enrolled in this study. A preoperative staging work-up was conducted in 36 patients. All patients were treated with preoperative chemoradiotherapy, and curative resection was performed for 26 patients at Hallym University Sacred Heart Hospital. Radiotherapy treatment planning was conducted with the use of planning CT for all patients. A total dose of $45.0{\sim}52.2\;Gy$ conventionally fractionated three-dimensional radiotherapy was delivered to the whole pelvis. Chemotherapy was given at the first and fifth week of radiation therapy with continuous infusion i.v. 5-FU (Fluorouracil) and LV (Leucovorine). Surgical resection was performed 2 to 4 weeks after the completion of the chemoradiotherapy regimen. $\underline{Results}$: The complete resection rate with negative resection margin was 100% (26/26). However, a pathologically complete response was not seen after curative resection. Surgery was done by LAR (low anterior resection) in 23 patients and APR (abdomino-perineal resection) in 3 patients. The sphincter preservation rate was 88.5% (23/26), down staging of the tumor occurred in 12 patients (46.2%) and down-sizing of the tumor occurred in 19 patients (73%). Local recurrence after surgical resection developed in 1 patient, and distant metastasis developed in 3 patients. The local recurrence free survival rate, distant metastasis free survival rate, and progression free survival rate were 96.7%, 87% and 83.1%, respectively. Treatment related toxicity was minimal except for one grade 3, one grade 4 anemia, one grade 3 leukopenia, and one grade 3 ileus. $\underline{Conclusion}$: Preoperative concurrent chmoradiotherapy for locally advanced rectal cancer seems to have some potential benefits: high sphincter preservation and down staging. Treatment related toxicity was minimal and a high compliance with treatment was seen in this study. Further long-term follow-up with a larger group of patients is required.

키워드

참고문헌

  1. Gastrointestinal Tumor Study Group. Prolongation of disease- free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1464- 1472 https://doi.org/10.1056/NEJM198505303122227
  2. Medical Research Council Rectal Cancer Working Party. Randomized trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 1996;348:1610- 1614 https://doi.org/10.1016/S0140-6736(96)05349-4
  3. Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resection of rectal cancer. Cancer 1984;53:1354- 1362 https://doi.org/10.1002/1097-0142(19840315)53:6<1354::AID-CNCR2820530623>3.0.CO;2-J
  4. Stockholm Rectal Cancer Study Group. Preoperative shortterm radiotherapy in operable rectal carcinoma: a prospective randomized trial. Cancer 1990;66:49- 55 https://doi.org/10.1002/1097-0142(19900701)66:1<49::AID-CNCR2820660111>3.0.CO;2-1
  5. Mendenhall WM, Million RR, Bland KI, Pfaff EE, Copelnad EM. Preoperative radiation therapy for clinically resectable adenocarcinoma of the rectum. Ann Surg 1985;202: 25- 222
  6. Valentini V, Coco C, Picchiocchi A, et al. Does down staging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long- term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002;53:664- 674 https://doi.org/10.1016/S0360-3016(02)02764-5
  7. Mohiuddin M, Hayne M, Regine WF, et al. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J RadiatOncol Biol Phys 2000;48:1075- 1080 https://doi.org/10.1016/S0360-3016(00)00732-X
  8. Minsky BD, Cohen AM, Enker WE, Sigurdson E. Phase I/II trial of preoperative radiation therapy and coloanal anastomosis in distal invasive resectable rectal cancer. Int J Radiat Oncolo Biol Phys 1992;23:387- 392 https://doi.org/10.1016/0360-3016(92)90757-9
  9. Minsky BD, Kemeny N, Cohen AM, et al. Preoperative high- dose leucovorin/5- fluorouracil and radiation therapy for unresectable rectal cancer. Cancer 1991;67:2859- 2866 https://doi.org/10.1002/1097-0142(19910601)67:11<2859::AID-CNCR2820671126>3.0.CO;2-W
  10. Kelsen DP, Hilaris B, Martini N. Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Semin Surg Oncol 1986;2:170- 176 https://doi.org/10.1002/ssu.2980020310
  11. Marks G, Mohiuddin M, Rakinic J. New hope and promise for sphincter preservation in the management of cancer of the rectum. Semin Oncol 1991;18:388- 398
  12. Cohen AM, Minsky BD, Friedman MA. Cancer of breast. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principle & Practice of Oncology. 4th ed. Philadelphia, PA: Lippincot Co. 1993:1264- 1332
  13. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980- 987 https://doi.org/10.1056/NEJM199704033361402
  14. Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: longterm follow- up of a population- based study. Cancer 2001;92:896- 902 https://doi.org/10.1002/1097-0142(20010815)92:4<896::AID-CNCR1398>3.0.CO;2-R
  15. Colorectal Cancer Collaborative Goup. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001;358:1291- 1304 https://doi.org/10.1016/S0140-6736(01)06409-1
  16. Camma C, Guinta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta- analysis. JAMA 2000;284:1008- 1015 https://doi.org/10.1001/jama.284.8.1008
  17. Luna Perez P, Rodriguez Ramirez S, Rodriguez Coria DF, et al. Preoperative chemoradiation therapy and anal sphincter preservation with locally advanced rectal adenocarcinoma. World J Surg 2001;25:1006-1011 https://doi.org/10.1007/s00268-001-0071-y
  18. Rullier E, Goffre B, Bonnel C, Zerbib F, Caudry M, Saric J. Preoperative radiochemotherapy and sphincter- saving resection for T3 carcinomas of the lower third of the rectum. Ann Surg 2001;234:633- 640 https://doi.org/10.1097/00000658-200111000-00008
  19. Wassif SB. The role of preoperative adjuvant therapy in the management of borderline operability rectal cancer. Clin Radiol 1982;33:353- 358 https://doi.org/10.1016/S0009-9260(82)80289-4
  20. Boulis Wassif S, Gerard A, Loygue J, Camelot D, Buyse M, Duez N. Final results of a randomized trial on the treatement of rectal cancer with preoperative radiotherapy alone or in combination with 5- fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Cancer 1984;53:1811- 1818 https://doi.org/10.1002/1097-0142(19840501)53:9<1811::AID-CNCR2820530902>3.0.CO;2-H
  21. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short- term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004;72:15- 24 https://doi.org/10.1016/j.radonc.2003.12.006
  22. Boset JF, Collette L, Calais G, Mineuer L, et al. Chemotherapy with preoperative radiotherapy in recal cancer. N Engl J Med 2006;355:1114- 1123 https://doi.org/10.1056/NEJMoa060829
  23. Cho JH, Seong J, Keum KC, et al. Efficacy of a preoperative concurrent chemoradiotherapy for the locally advanced unresectable rectal cancer. J Korean Soc Ther Radiol Oncol 2000;18:293- 299
  24. Cho HM, Kim GK, Jung H, et al. The effect of preoperative concurrent chemoradiation in locally advanced rectal cancer. J Korean Soc Coloproctol 2005;21:89- 99
  25. Kay CS, Choi IB, Jang JY, et al. The effects of preoperative radiation therapy in resectable rectal cancer: in view of pathologic aspects. J Korean Soc Ther Radiol Oncol 1997;15:49- 56
  26. Yu CS, Kim JH, Lee JH, et al. Efficacy of preoperative radiochemotherapy in patients with advanced low rectal cancer. J Korean Soc Coloproctol 2004;20:46- 51
  27. Kang KM, Choi BO, Jang HS, Kang NK, Chai KY, Choi IB. Effect of peroperative radiotherapy for T2, T3 distal rectal cancer. J Korean Soc Ther Radiol Oncol 2002;20:215- 220
  28. Yun HG. Results of preoperative chemoradiotherapy in low rectal cancer. J Korean Soc Ther Radiol Oncol 2006;24:21- 29
  29. Lee DR, Lee HI, Kim HG, et al. Clinical results of preoperative chemoradiation on advanced rectal cancers; tumor responses, toxicities, and mortality. J Korean Soc Coloproctol 2004;20:138- 144
  30. Shin SS, Ahn YC, Chun HK, et al. Preoperative concurrent radio- chemotherapy for rectal cancer: report of early results. J Korean Soc Ther Radiol Oncol 2003;21:125- 134
  31. Kim IY, Shin DG, Park KR, Sung SH, Chu YK, Kim DS. Preoperative chemoradiation therapy in the management of locally advanced rectal cancer. J Korean Soc Coloproctol 2005;21:19- 26
  32. Roman S, Cenni JC, Roy P, et al. Value of rectal ultrasound in predicting staging and outcome in patients with rectal adenocarcinoma. Dis Colon Rectum 2004;47:1323- 1330 https://doi.org/10.1007/s10350-004-0583-2
  33. Branagan G, Chave H, Fuller C, McGee S, Finnis D. Can magnetic resonance imaging predict circumferential margins and TMN stage in rectal cancer? Dis Colon Rectum 2004;47:1317- 1322 https://doi.org/10.1007/s10350-004-0594-z
  34. Heriot AG, Grundy A, Kumar D. Preoperative staging of rectal carcinoma. Br J Surg 1999;86:17- 28 https://doi.org/10.1046/j.1365-2168.1999.00996.x
  35. Berger C, de Muret A, Garaud P, et al. Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. Int J Radiat Oncol Biol Phys 1997;37:619- 627 https://doi.org/10.1016/S0360-3016(96)00577-9
  36. Mohiuddin M, Regine WF, John WJ, et al. Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. Int J Radiat Oncol Biol Phys 2000;46:883- 888 https://doi.org/10.1016/S0360-3016(99)00486-1
  37. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter- sparing surgery for rectal cancer: the Lyon R90- 01 randomized trial. J Clin Oncol 1999;17:2396- 2402 https://doi.org/10.1200/JCO.1999.17.8.2396
  38. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279- 286 https://doi.org/10.1007/s10350-003-0062-1
  39. Chao M, Gibbs P, Tjandra J, Darben P, Lim-Joon D, Jones IT. Evaluation of the use of computed tomography versus conventional X- ray simulation in the treatment of rectal cancer. Radiat Oncol 2005;49:122- 126